Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20

被引：28

作者：

Marcelin, AG ^{[1
]}

Reynes, J

Yerly, S

Ktorza, N

Segondy, M

Piot, JC

Delfraissy, JF

机构：

[1] Grp Hosp Pitie Salpetriere, F-75634 Paris, France

[2] CHU Montpellier, Montpellier, France

[3] Univ Hosp Geneva, Geneva, Switzerland

[4] Kremlin Bicetre Hosp, Villejuif, France

来源：

AIDS | 2004年 / 18卷 / 09期

关键词：

D O I：

10.1097/00002030-200406180-00015

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We analysed the genetic changes in gp41 in a population of 30 heavily pretreated HIV-1-infected patients failing on a T-20-containing salvage therapy. This study confirms the key role of the number of drugs presumed to be still effective associated with T-20 in the magnitude of the virological response. Our results suggest that only HR-1 sequencing is necessary to characterize resistance to T-20, and that HR-2 domain sequencing is probably not required.

引用

页码：1340 / 1342

页数：3

共 10 条

[1]

Cervia JS, 2003, CLIN INFECT DIS, V37, P1102, DOI 10.1086/378302

[2]

GREENBERG ML, 2002, 11 INT HIV DRUG RES

[3] Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:: 2003 recommendations of an international AIDS Society-USA panel [J].

Hirsch, MS ;

Brun-Vézinet, F ;

Clotet, B ;

Conway, B ;

Kuritzkes, DR ;

D'Aquila, RT ;

Demeter, LM ;

Hammer, SM ;

Johnson, VA ;

Loveday, C ;

Mellors, JW ;

Jacobsen, DM ;

Richman, DD .

CLINICAL INFECTIOUS DISEASES, 2003, 37 (01) :113-128

[4] Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America [J].

Lalezari, JP ;

Henry, K ;

O'Hearn, M ;

Montaner, JSG ;

Piliero, PJ ;

Trottier, B ;

Walmsley, S ;

Cohen, C ;

Kuritzkes, DR ;

Eron, JJ ;

Chung, J ;

DeMasi, R ;

Donatacci, L ;

Drobnes, C ;

Delehanty, J ;

Salgo, M ;

Farthing, C ;

Graham, E ;

Packard, M ;

Ngo, L ;

Lederman, M ;

Buam, J ;

Pollard, R ;

Rauf, S ;

Silkowski, W ;

Thompson, M ;

Rucker, A ;

Harris, M ;

Larsen, G ;

Preseon, S ;

Cunningham, D ;

Guimaraes, D ;

Bertasso, A ;

Kinchelow, T ;

Myers, R ;

Phoenix, BCBP ;

Skolnik, PR ;

Adams, B ;

Leite, OHM ;

Oliveira, M ;

Lefebvre, E ;

Gomez, B ;

Foy, KB ;

Lampiris, H ;

Charles, S ;

Dobkin, J ;

Crawford, M ;

Slom, T ;

Murphy, R ;

Mikaitis, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (22) :2175-2185

[5] Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia [J].

Lazzarin, A ;

Clotet, B ;

Cooper, D ;

Reynes, J ;

Arasteh, K ;

Nelson, M ;

Katlama, C ;

Stellbrink, H ;

Delfraissy, J ;

Lange, J ;

Huson, L ;

DeMasi, R ;

Wat, C ;

Delehanty, J ;

Drobnes, C ;

Salgo, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (22) :2186-2195

[6]

LU J, 2002, 11 INT HIV DRUG RES

[7] Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptide [J].

Rimsky, LT ;

Shugars, DC ;

Matthews, TJ .

JOURNAL OF VIROLOGY, 1998, 72 (02) :986-993

[8]

SISTA P, 2003, 12 INT HIV DRUG RES

[9]

STANFIELDOAKLEY SA, 2003, 12 INT HIV DRUG RES

[10] Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy [J].

Wei, XP ;

Decker, JM ;

Liu, HM ;

Zhang, Z ;

Arani, RB ;

Kilby, JM ;

Saag, MS ;

Wu, XY ;

Shaw, GM ;

Kappes, JC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1896-1905

← 1 →